SCHEMBL22804300

SCHEMBL22804300

CCC(F)(F)c1cc(F)c(F)cc1OC(C)C(=O)O

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 1/20 0.39
PTGDR2 Q9Y5Y4 5/20 0.38
TSHR P16473 1/20 0.38
HTR2A P28223 1/20 0.38
HTR2C P28335 1/20 0.38
HTR2B P41595 1/20 0.38
ABCB11 O95342 1/20 0.37
KDM4E B2RXH2 3/20 0.36
ALDH1A1 P00352 3/20 0.36
HSD17B10 Q99714 3/20 0.36
HPGD P15428 2/20 0.36
RAB9A P51151 1/20 0.36
TDP1 Q9NUW8 1/20 0.36
PPARA Q07869 3/20 0.35
PPARD Q03181 2/20 0.35
PDK2 Q15119 1/20 0.34
PPARG P37231 1/20 0.34
MGLL Q99685 1/20 0.34
POLB P06746 1/20 0.33
NR1H4 Q96RI1 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22804299 1.00 KMT2A (0.39) KMT2APTGDR2TSHRHTR2AHTR2C
SCHEMBL28672447 0.89 PTGDR2 (0.42) KMT2APTGDR2TSHRHTR2AHTR2C
SCHEMBL28672449 0.89 PTGDR2 (0.42) KMT2APTGDR2TSHRHTR2AHTR2C
SCHEMBL29365346 0.89 PTGDR2 (0.42) KMT2APTGDR2TSHRHTR2AHTR2C
SCHEMBL28677988 0.89 PTGDR2 (0.42) KMT2APTGDR2TSHRHTR2AHTR2C
SCHEMBL28677987 0.89 PTGDR2 (0.42) KMT2APTGDR2TSHRHTR2AHTR2C
SCHEMBL22823914 0.89 AAK1 (0.36) KMT2APTGDR2TSHRHTR2AHTR2C
SCHEMBL22820787 0.89 AAK1 (0.36) KMT2APTGDR2TSHRHTR2AHTR2C
SCHEMBL29365429 0.89 AAK1 (0.36) KMT2APTGDR2TSHRHTR2AHTR2C
SCHEMBL22823852 0.86 F9 (0.39) TSHRKDM4EALDH1A1HSD17B10HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114008012-A Compounds for the treatment of neuromuscular disorders NMD制药股份公司 2022-02-01 CN claimed
US-12415771-B2 Compounds for the treatment of neuromuscular disorders NMD PHARMA A/S (DK) 2025-09-16 US disclosed
EP-3986852-B1 COMPOUNDS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS NMD PHARMA AS (DK) 2024-10-16 EP disclosed
US-20220388938-A1 COMPOUNDS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS NMD PHARMA A/S (DK) 2022-12-08 US disclosed
EP-3986852-A1 COMPOUNDS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS NMD Pharma A/S (DK) 2022-04-27 EP disclosed
CN-114008012-A Compounds for the treatment of neuromuscular disorders NMD制药股份公司 2022-02-01 CN disclosed
WO-2020254559-A1 COMPOUNDS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS NMD PHARMA A/S (DK) 2020-12-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220388938-A1 COMPOUNDS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS RYR1, CACNB1, SMN1; SMN2 KMT2A 3188/4885PTGDR2 2994/4885TSHR 3562/4885
US-12415771-B2 Compounds for the treatment of neuromuscular disorders RYR1, CACNB1, SMN1; SMN2 KMT2A 3188/4885PTGDR2 2994/4885TSHR 3562/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.